 
         Research Article
												The Pharmacokinetic Properties and Bioequivalence of Methyldopa
Formulations: Results of an Open-label, Randomized, Two-period,
Crossover, Single-dose Study 						
Author(s): Alexander Leonidovich  Khokhlov, Leonid Nikolaevich  Shitov, Miroslav  Ryska, Yuriy Aleksandrovich  Dzhurko, VladimÃÂr Kube&scaron, Vitaliy Nikolaevich  Shabrov, Aleksey Evgenyevich  Miroshnikov, Elena Valeryevna  Korneva, Anna Vitalyevna  Demchinskaya, Anastasiya Mikhailovna  Shitova, Igor Evgenyevich  Shokhin and Elena Georgievna  LileevaAlexander Leonidovich  Khokhlov, Leonid Nikolaevich  Shitov, Miroslav  Ryska, Yuriy Aleksandrovich  Dzhurko, VladimÃr Kube&scaron, Vitaliy Nikolaevich  Shabrov, Aleksey Evgenyevich  Miroshnikov, Elena Valeryevna  Korneva, Anna Vitalyevna  Demchinskaya, Anastasiya Mikhailovna  Shitova, Igor Evgenyevich  Shokhin and Elena Georgievna  Lileeva             
						
												
				 Comparative assessment of the pharmacokinetic properties and bioequivalence (BE) of two methyldopa formulations (Methyldopa, 250 mg tablets, R-Pharm CJSC, Russia-investigational medicinal product, and Dopegyt®, 250 mg tablets, EGIS Pharmaceuticals PLC, Hungary-reference product) were investigated in 24 healthy volunteers (13 women and 11 men, caucasian) in an open-label, randomized, crossover, two-period, two-sequence trial with 7-day washout period. A comparative dissolution test was carried out in advance in 3 media, including quantitative determination of methyldopa by UV spectrophotometry. The release patterns of the active ingredient from the test and reference products were equivalent. Methyldopa concentrations in plasma were measured by validated method of high-performance liquid chromatography-tandem mass spectrometry, using the deuterated internal standard. The validation.. View More»